{"product_id":"antibodymediated-drug-delivery-systems-9780470612811","title":"AntibodyMediated Drug Delivery Systems","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis book covers various aspects of antibody mediated drug delivery systems  theoretical aspects, processing, viral and non-viral vectors, and fields where these systems find and \/or are being evaluated for applications as therapeutics and diagnostic treatment. Chapters discuss actual applications of techniques used for formulation and characterization. Applications areas include cancer, pulmonary, ocular diseases; brain drug delivery; and vaccine delivery. The contributing authors represent over 10 different countries, covering recent developments happening around the globe.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eCONTRIBUTORS xv\u003c\/p\u003e \u003cp\u003ePREFACE xix\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 1 ANTIBODY-MEDIATED DRUG DELIVERY SYSTEMS: GENERAL REVIEW AND APPLICATIONS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eNavdeep Kaur, Karthikeyan Subramani, and Yashwant Pathak 1\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Historical Perspective 1\u003c\/p\u003e \u003cp\u003e2 Antibodies 2\u003c\/p\u003e \u003cp\u003e3 Antibody Mediation 3\u003c\/p\u003e \u003cp\u003e4 Antibody-Mediated Drug Delivery Systems 4\u003c\/p\u003e \u003cp\u003e5 Applications 6\u003c\/p\u003e \u003cp\u003e6 Recent Trends 9\u003c\/p\u003e \u003cp\u003e7 Future Trends 10\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 2 IMMUNOLIPOSOMES FOR CARDIOVASCULAR TARGETING\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eTatyana Levchenko, William Hartner, and Vladimir P. Torchilin 13\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 13\u003c\/p\u003e \u003cp\u003e2 Immunoliposome Targeting to Pathological Regions of the Vessel Wall 14\u003c\/p\u003e \u003cp\u003e3 Liposome Internalization by Endothelial Cells 15\u003c\/p\u003e \u003cp\u003e4 Targeting of Atherosclerotic Lesions for Tomographic Imaging 17\u003c\/p\u003e \u003cp\u003e5 Antibody-Mediated Liposomes for Diagnosis of Thrombosis 17\u003c\/p\u003e \u003cp\u003e6 Thrombolytic Therapy with Immunoliposomes 18\u003c\/p\u003e \u003cp\u003e7 Targeted Sealing of Cell Membrane Lesions: Preservation of Cell Viability 19\u003c\/p\u003e \u003cp\u003e8 Accumulation of Liposomes and Immunoliposomes in the Ischemic Heart 21\u003c\/p\u003e \u003cp\u003e9 Immunoliposomes as a Drug and Gene Delivery Vehicle to the Infarcted Heart 26\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 3 ANTIBODY-MEDIATED DRUG DELIVERY SYSTEMS FOR BREAST CANCER THERAPEUTICS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eLeonor Munoz Alcivar and Yashwant Pathak 35\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 35\u003c\/p\u003e \u003cp\u003e2 Breast Cancer 35\u003c\/p\u003e \u003cp\u003e3 Drug Delivery Systems 36\u003c\/p\u003e \u003cp\u003e4 Monoclonal Antibodies 37\u003c\/p\u003e \u003cp\u003e5 Human Epidermal Growth Factor Receptor 2 40\u003c\/p\u003e \u003cp\u003e6 Antibody-Mediated Drug Delivery System 43\u003c\/p\u003e \u003cp\u003e7 Targets for the Treatment of Breast Cancer 45\u003c\/p\u003e \u003cp\u003e8 Breast Cancer Therapies 46\u003c\/p\u003e \u003cp\u003e9 The Future of Breast Cancer Therapeutics 49\u003c\/p\u003e \u003cp\u003e10 Other Treatment Strategies 50\u003c\/p\u003e \u003cp\u003e11 Nanotechnology 51\u003c\/p\u003e \u003cp\u003e12 Conclusions 52\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 4 DEVELOPMENT OF IMMUNONCONJUGATES FOR IN VIVO DELIVERY: CANCER DIAGNOSIS, IMAGING, AND THERAPY\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eArutselvan Natarajan 57\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 57\u003c\/p\u003e \u003cp\u003e2 Immunoconjugates 61\u003c\/p\u003e \u003cp\u003e3 Immunoconjugates in Cancer Therapy 62\u003c\/p\u003e \u003cp\u003e4 Immunoconjugates for Imaging 69\u003c\/p\u003e \u003cp\u003e5 Immunoconjugates in Diagnostic Applications 71\u003c\/p\u003e \u003cp\u003e6 Immunoconjugates’ Promising Future and Challenges 72\u003c\/p\u003e \u003cp\u003e7 Summary 73\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 5 MATHEMATICAL MODELS OF ANTI-TNF THERAPIES AND THEIR CORRELATION WITH TUBERCULOSIS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSimeone Marino, Mohammad Fallahi-Sichani, Jennifer J. Linderman, and Denise E. Kirschner 83\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 83\u003c\/p\u003e \u003cp\u003e2 Tuberculosis, TNF, and Anti-TNF Drugs 84\u003c\/p\u003e \u003cp\u003e3 Theoretical Models To Study TB Infection 88\u003c\/p\u003e \u003cp\u003e4 Present and Future Work 96\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 6 TARGETED NANOPARTICLES IN RADIOTHERAPY\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMisty Muscarella and Yashwant Pathak 105\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 105\u003c\/p\u003e \u003cp\u003e2 Nanoparticles 106\u003c\/p\u003e \u003cp\u003e3 Radiotherapy 110\u003c\/p\u003e \u003cp\u003e4 Nanoparticles in Radiotherapy 111\u003c\/p\u003e \u003cp\u003e5 Current and Future Developments with Nanotechnology in Radiotherapy 123\u003c\/p\u003e \u003cp\u003e6 Conclusions 124\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 7 ELECTRICALLY-ENHANCED DELIVERY OF DRUGS AND CONJUGATES FOR CANCER TREATMENT\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eArutselvan Natarajan, Luca Campana, and Raji Sundararajan 129\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 129\u003c\/p\u003e \u003cp\u003e2 Electroporation Mechanisms to Permeabilize the Drugs and DNAs in Cells 130\u003c\/p\u003e \u003cp\u003e3 Electroporation-Aided Drug Delivery for Preclinical Studies 133\u003c\/p\u003e \u003cp\u003e4 EP applications for Human Patient Studies 136\u003c\/p\u003e \u003cp\u003e5 Future Perspectives 138\u003c\/p\u003e \u003cp\u003e6 Summary 139\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 8 CHARACTERIZATION OF MONOCLONAL ANTIBODY VARIANTS AND GLYCOSYLATION\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eTing Zheng, Srinivasa Rao, Jeff Rohrer, and Chris Pohl 145\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Characterization of Monoclonal Antibody Heterogeneity by HPLC Analysis 145\u003c\/p\u003e \u003cp\u003e2 Analysis of Monoclonal Antibody Glycosylation 150\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 9 ANTIBODY-MEDIATED DRUG DELIVERY SYSTEM FOR LYMPHATIC TARGETING TREATMENT\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eFang Wu, Hong Ding, and Zhirong Zhang 169\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 169\u003c\/p\u003e \u003cp\u003e2 Lymphatic Disorders and Their Normal Treatment 170\u003c\/p\u003e \u003cp\u003e3 Antibody-Mediated Drug Delivery Systems for Lymphatic Targeting Treatment 172\u003c\/p\u003e \u003cp\u003e4 Conclusions and Future Perspectives 183\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 10 METHODS FOR NANOPARTICLE CONJUGATION TO MONOCLONAL ANTIBODIES\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJunling Li and Chin K. Ng 191\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 191\u003c\/p\u003e \u003cp\u003e2 Current Nanoparticle Systems used for Conjugation with mAbs 191\u003c\/p\u003e \u003cp\u003e3 Conjugation Methods 192\u003c\/p\u003e \u003cp\u003e4 Conclusions 202\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 11 SINGLE-USE SYSTEMS IN ANIMAL CELL–BASED BIOPRODUCTION\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eWilliam G. Whitford 209\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 209\u003c\/p\u003e \u003cp\u003e2 Component Offerings 214\u003c\/p\u003e \u003cp\u003e3 Characteristics of Single-Use Systems and Their Applications 218\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 12 IMMUNOLIPOSOMES FOR SPECIFIC DRUG DELIVERY\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eManuela Calin 229\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction: Advances in Liposome Formulation 229\u003c\/p\u003e \u003cp\u003e2 Design of Immunoliposomes for Site-Specific Drug Delivery 230\u003c\/p\u003e \u003cp\u003e3 Cellular-Specific Targeting of Immunoliposomes 242\u003c\/p\u003e \u003cp\u003e4 Cellular-Specific Internalization of Immunoliposomes 246\u003c\/p\u003e \u003cp\u003e5 Immunoliposomes in Diagnosis and Therapy 247\u003c\/p\u003e \u003cp\u003e6 Clinical Use of Immunoliposomes 251\u003c\/p\u003e \u003cp\u003e7 Conclusions and Perspectives 252\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 13 GENE THERAPY TARGETING KIDNEY DISEASES: ROUTES AND VEHICLES\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eYoshitaka Isaka, Yoshitsugu Takabatake, and Hiromi Rakugi 267\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 267\u003c\/p\u003e \u003cp\u003e2 Rationale for Successful Gene Targeting 268\u003c\/p\u003e \u003cp\u003e3 Site-Specific Gene Delivery 268\u003c\/p\u003e \u003cp\u003e4 Nuclear Import of Gene Material 270\u003c\/p\u003e \u003cp\u003e5 Targeting the Glomerulus 270\u003c\/p\u003e \u003cp\u003e6 Targeting the Tubule 272\u003c\/p\u003e \u003cp\u003e7 Targeting the Interstitium 274\u003c\/p\u003e \u003cp\u003e8 Targeting Muscle 274\u003c\/p\u003e \u003cp\u003e9 Conclusions 275\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 14 DETECTION OF ANTIBODIES TO POLY(ETHYLENE GLYCOL) POLYMERS USING DOUBLE-ANTIGEN-BRIDGING IMMUNOGENICITY ELISA\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eYijuan Liu, Helen Reidler, Jing Pan, David Milunic, Dujie Qin, Dave Chen, Yli Remo Vallejo, and Ray Yin 279\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 279\u003c\/p\u003e \u003cp\u003e2 Methods 280\u003c\/p\u003e \u003cp\u003e3 Results 283\u003c\/p\u003e \u003cp\u003e4 Discussion 286\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 15 ANTIBODIES IN NANOMEDICINE AND MICROIMAGING METHODS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eRakesh Sharma 291\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction: Antibody Molecules and Nanoparticles 291\u003c\/p\u003e \u003cp\u003e2 Antibody-Based Nanoparticles in Microimaging 292\u003c\/p\u003e \u003cp\u003e3 Troponin T: Newer Magnetic Immunoassay Method 317\u003c\/p\u003e \u003cp\u003e4 Gold Nanoparticles as an Antigen Carrier and Adjuvant 330\u003c\/p\u003e \u003cp\u003e5 Immunochemical Biosensors, Nanomedicine, and Disease 339\u003c\/p\u003e \u003cp\u003e6 Future Directions and Conclusions 341\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 16 METHODS FOR POLYMERIC NANOPARTICLE CONJUGATION TO MONOCLONAL ANTIBODIES\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eUyen Minh Le, Hieu Tran, and Yashwant Pathak 351\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 351\u003c\/p\u003e \u003cp\u003e2 Conjugation of mAb and Polyethylenimine Nanoparticles 353\u003c\/p\u003e \u003cp\u003e3 Conjugation of mAb to Poly(Lactide-CO-Glycolide) Nanoparticles 357\u003c\/p\u003e \u003cp\u003e4 Conjugation of mAb to Poly(Lactic Acid) and its Derivatives 359\u003c\/p\u003e \u003cp\u003e5 Conjugation of mAb to Other Polymeric Nanoparticles 360\u003c\/p\u003e \u003cp\u003e6 Summary 361\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 17 PLANT-DERIVED ANTIBODIES FOR ACADEMIC, INDUSTRIAL, AND THERAPEUTIC APPLICATIONS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSlavko Komarnytsky and Nikolai Borisjuk 365\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Historical Perspective 365\u003c\/p\u003e \u003cp\u003e2 Plant-Based Production of Recombinant Proteins 366\u003c\/p\u003e \u003cp\u003e3 Expression in an Entire Plant Versus a Plant Organ 367\u003c\/p\u003e \u003cp\u003e4 ER Targeting and Secretion of Recombinant Proteins 368\u003c\/p\u003e \u003cp\u003e5 Expression in Seeds 370\u003c\/p\u003e \u003cp\u003e6 Transient Expression 371\u003c\/p\u003e \u003cp\u003e7 Glycosylation 373\u003c\/p\u003e \u003cp\u003e8 Recent Examples of Plant-Derived Antibodies Effective in Mammalian Systems 375\u003c\/p\u003e \u003cp\u003e9 Conclusions 376\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 18 MONOCLONAL ANTIBODIES AS BIOPHARMACEUTICALS\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eGirish J. Kotwal 383\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Historical Perspective 383\u003c\/p\u003e \u003cp\u003e2 Introduction 384\u003c\/p\u003e \u003cp\u003e3 Structure and Types of mAbs 385\u003c\/p\u003e \u003cp\u003e4 Mechanism of Action 385\u003c\/p\u003e \u003cp\u003e5 FDA-approved mAb Biopharmaceuticals in Current Use 386\u003c\/p\u003e \u003cp\u003e6 Future of Monoclonal Antibodies as Biopharmaceuticals 389\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 19 PULMONARY TARGETING OF NANOPARTICLES AND MONOCLONAL ANTIBODIES\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eWeiyuan Chang 391\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 391\u003c\/p\u003e \u003cp\u003e2 Attributes of mAbs as Therapeutics for Pulmonary Diseases 392\u003c\/p\u003e \u003cp\u003e3 Antibody-Conjugated Nanoparticles for Lung Targeting 393\u003c\/p\u003e \u003cp\u003e4 Monoclonal Antibodies in the Treatment of Asthma 394\u003c\/p\u003e \u003cp\u003e5 Monoclonal Antibodies in the Treatment of COPD 398\u003c\/p\u003e \u003cp\u003e6 Challenges in Pulmonary Disease 400\u003c\/p\u003e \u003cp\u003e7 Conclusions 402\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 20 ANTIBODY-MEDIATED ARTHRITIS AND NEW THERAPEUTIC AVENUES\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKutty Selva Nandakumar 407\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Autoantibodies in Rheumatoid Arthritis 407\u003c\/p\u003e \u003cp\u003e2 Role of Cartilage Antigen-Specific Antibodies in Inducing Arthritis 408\u003c\/p\u003e \u003cp\u003e3 Arthritis Mediation Through Antibodies Recognizing Citrullinated Antigens 413\u003c\/p\u003e \u003cp\u003e4 Regulation at the Effector Level 414\u003c\/p\u003e \u003cp\u003e5 Cartilage Damage Independent of Inflammatory Mediators 414\u003c\/p\u003e \u003cp\u003e6 pathogenicity of GPI-Specific Antibodies 415\u003c\/p\u003e \u003cp\u003e7 Therapeutic Cleavage of Arthritogenic Antibodies 415\u003c\/p\u003e \u003cp\u003e8 Arthritis Attenuation Though Removal of Specific Sugars on IgG 417\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 21 IMMUNONANOPARTICLES FOR NUCLEAR IMAGING AND RADIOTHERAPY\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eOren Giladi and Simon Benita 427\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Radioisotopes and Radiopharmaceuticals 427\u003c\/p\u003e \u003cp\u003e2 Radiolabeled Antibodies 432\u003c\/p\u003e \u003cp\u003e3 Radiolabeled Nanoparticles 437\u003c\/p\u003e \u003cp\u003e4 Future Perspectives and Conclusions 449\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCHAPTER 22 MONOCLONAL ANTIBODIES IN THE TREATMENT OF ASTHMA\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eGlenn J. Whelan 457\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction 457\u003c\/p\u003e \u003cp\u003e2 IgE 458\u003c\/p\u003e \u003cp\u003e3 TNFα 460\u003c\/p\u003e \u003cp\u003e4 IL-5 462\u003c\/p\u003e \u003cp\u003e5 IL-9 464\u003c\/p\u003e \u003cp\u003e6 IL-4 and IL-13 465\u003c\/p\u003e \u003cp\u003e7 Targeting the T-cell 467\u003c\/p\u003e \u003cp\u003e8 Conclusions 468\u003c\/p\u003e \u003cp\u003eReferences 469\u003c\/p\u003e \u003cp\u003e\u003cb\u003eINDEX 473\u003c\/b\u003e\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402378879319,"sku":"9780470612811","price":128.66,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470612811.jpg?v=1730480213","url":"https:\/\/bookcurl.com\/products\/antibodymediated-drug-delivery-systems-9780470612811","provider":"Book Curl","version":"1.0","type":"link"}